ArticleHeliyon2024
Brain volume loss in Japanese patients with multiple sclerosis is present in the early to middle stage of the disease.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Background: To determine which disease-modifying therapies should be used in patients with multiple sclerosis (MS), identifying patients at high and low risk for brain volume loss (BVL) is important. Although the BVL rate in MS is nearly constant from early to late disease onset, regardless of the disease stage, individual differences have been noted. Moreover, as disease duration increases, the risk of chronic progression increases, and brain atrophy becomes more noticeable. Therefore, measuring prognosis using a classification that considers BVL rate and disease duration is appropriate. We aimed to investigate the BVL in Japanese patients with MS. Methods: Herein, with an observational period of approximately 3.5 years, 82 Japanese patients with MS were included. The volumes and annualised volume changes (AVCs) of the grey matter (GM) and whole brain were evaluated using ico Results: Whole-brain AVCs varied, especially among patients with a disease duration within approximately 16 years. Cluster analysis using two variables, disease duration and whole-brain AVC, identified the SM (short to middle duration and mild atrophy rates), SS (short to middle duration and severe atrophy rates), and L (long duration) groups. The optimal cut-off values for disease duration and whole-brain AVC to discriminate among the three groups were 15.8 years and -0.43%, respectively. Compared with the SM group, the SS group had higher Multiple Sclerosis Severity Scale (MSSS) and Expanded Disability Status Scale (EDSS) scores, lower information processing speed (IPS), higher lesion loads, higher whole-brain and GM volume loss, and higher GM atrophy rates. Moreover, among the 63 patients with MS included in the SM and SS groups, whole-brain AVCs were significantly correlated with the EDSS and MSSS scores and IPS. Conclusion: BVL rates vary, especially among Japanese patients with MS with short to middle disease duration, and BVL degree is associated with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.